Advertisement

Topics

U.S. court invalidates patent on J&J cancer drug Zytiga

18:24 EST 17 Jan 2018 | Reuters

NEW YORK (Reuters) - A U.S. administrative court on Wednesday invalidated a Johnson & Johnson patent on its blockbuster prostate cancer drug Zytiga, bringing rivals closer to selling generic versions.

Original Article: U.S. court invalidates patent on J&J cancer drug Zytiga

NEXT ARTICLE

More From BioPortfolio on "U.S. court invalidates patent on J&J cancer drug Zytiga"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...